Navigation Links
TRICAST Debuts Part D Rejection Oversight Solution for Drug Plan Sponsors
Date:8/13/2012

MILWAUKEE, Aug. 13, 2012 /PRNewswire/ -- Recent civil money penalties levied by the Centers for Medicare & Medicaid Services (CMS) against a major Prescription Drug Plan (PDP) sponsor have hammered home the fact that CMS is not taking rejection analysis lightly. To help Medicare Advantage and stand-alone PDP sponsors respond to this new vigilance, TRICAST is offering a sound PBM oversight solution.

Primary Rejection Analytics

Rejection analysis and reporting is a crucial component of TRICAST's PBM oversight process. TRICAST reviews rejected Medicare Part D prescription transactions to ensure that plan management is aligned with appropriate plan design adherence. Their trained staff analyzes rejected prescription transactions to ensure that the six protected classes (Antidepressants, Antipsychotics, Anticonvulsants, Antiretroviral, Immunosuppressants, Anticancer) are not affected. TRICAST also analyzes and reports on rejected claims during a plan enrollee's transition period.

After a rejection analysis, TRICAST is able to determine if the majority of drugs were -- or were not -- covered. They also load and display all secondary messaging sent to the pharmacy provider to further support the oversight process.

TRICAST provides their analysis in reports that contain pivot tables, analyzing the type of reject by pharmacy and its timeframe. These pivot tables not only provide a breakdown of reason codes and a summary of the count of rejects, they also allow for actionable results, review, and resolution.

Complete Transition Patient Analysis

TRICAST loads all relevant eligibility to provide a complete third-party Transition Patient analysis. Inclusion of Transaction Reply Reports (TRR), Monthly Membership Reports (MMR) and Medicare Advantage and Prescription Drug (MARx) files the system portrays any patient experiencing a change in plan design, group or enrollment as "Transition." These patients will then have a separate rejection analysis done to ensure oversight of transition compliance.

End-to-End Compliance

Including PDE and source claims on an ongoing basis enhances oversight and compliance through reporting of patient receipt of appropriate treatment post rejection. Compliance reporting supports the primary concern of patient treatment.

The TRICAST Solution

With so many alternatives to selecting Pharmacy Benefit program oversight auditors and consultants, how do you decide? The TRICAST team possesses a very unique combination of:

  • Deep domain focus on the pharmacy benefit industry
  • Highly developed software and tools tailored for PBM and program analysis that utilize 100% claim analysis
  • Experienced consulting and auditing perspective
  • Independence

Our background, coupled with our mission to address your complicated program issues with clear and actionable information, makes TRICAST an excellent partner.

About TRICAST

TRICAST, Inc. is a leading pharmacy data, analytics, and consulting firm founded in 1997. TRICAST has leveraged more than 25 years of technology and claims processing expertise, extensive client insight and a team of industry experts to offer forward-thinking, full-scope pharmacy benefit oversight solutions to our clients.

We provide audit services as the core of our business, and have assessed multiple types of pharmacy programs. Our broad experience across payors of widely differentiated size and type, combined with our focused experience in pharmacy, enables us to deliver a comprehensive assessment of pharmacy programs.  

Media Contact:

Kristin Karakis
TRICAST, Inc.
414.302.9733 ext. 245
kristin.karakis@tricast.com
http://www.tricast.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE TRICAST, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
2. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
3. Viztek Debuts Upgraded Opal-Ortho Appliance; Offers Small "One Box" Footprint for Private Practices Combining CR/DR and PACS
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
6. Stereotaxis Epoch™ Solutions Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
7. Brainybrawn, Inc. announces Launch of its Web based Medical College Information Management Solution (Sanvi MCIMS), as well as Receipt of Order for Its Comprehensive Restaurant Information Management Solution for Managing Chain of Restaurants (Sanvi
8. Cardinal Health Brings Resolution to Litigation with DEA Settlement
9. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
10. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
11. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... 29, 2017 In a move that promises ... compliance for veterinary practices of all sizes, Cubex LLC ... that makes TITAN,s expertise in physical security, drug diversion ... clients nationally. ... controlled substances is at risk today," said TITAN founder ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two ... in excess of $835 million in resolved debt for its clients. , Credit card ... of the categories of debt settled by the company. With more than a decade ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... Hill, CT (PRWEB) , ... September 19, 2017 ... ... support, today announced the winners of the Entrepreneur Innovation Awards (EIA), held this ... all of whom are Connecticut-based companies and entrepreneurs, presented their innovative project ideas ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a new ... we’re born, Nature gives us a full supply of melanin – in the back ... this natural glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown ...
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting its annual ... (SPBA) hosted “Expanding Your Success” with an educational emphasis. , The three-day ... best practices for third party administrators (TPAs) related to health plan management and ...
Breaking Medicine News(10 mins):